Tom 2, Nr 1 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-04-28
Wyświetlenia strony
762
Wyświetlenia/pobrania artykułu
70348
Usunięcie jajników podczas zabiegu histerektomii z przyczyn nieonkologicznych – bilans korzyści i strat
Ginekologia i Perinatologia Praktyczna 2017;2(1):9-15.
Streszczenie
Usunięcie macicy to jedna z najczęstszych interwencji chirurgicznych w ginekologii. Zazwyczaj wskazaniami do
zabiegu są schorzenia łagodne. Podczas każdego zabiegu histerektomii chirurg staje przed decyzją co do losu
jajników — w wielu przypadkach są one usuwane jednocześnie w ramach profilaktyki raka jajnika. W piśmiennictwie
można znaleźć argumenty wskazujące na istotność tej decyzji wobec dowodów na hormonalną aktywność
gonad także po menopauzie, niskie ryzyko rozwoju procesu złośliwego w populacji ogólnej i możliwe konsekwencje
ustania czynności hormonalnej jajników w wyniku interwencji chirurgicznej. Z drugiej strony grupa pacjentek
z podwyższonym ryzykiem raka jajnika, jajowodu i otrzewnej może odnieść niewątpliwą korzyść z wycięcia gonad
podczas zabiegu histerektomii.
Słowa kluczowe: histerektomiarak jajnikaobustronne usunięcie jajnikówchirurgiczna menopauzaprofilaktyka raka jajnika
Referencje
- Hickey M, Ambekar M, Hammond I. Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Hum Reprod Update. 2010; 16(2): 131–141.
- Jacoby V, Grady D, Wactawski-Wende J, et al. Oophorectomy vs Ovarian Conservation With Hysterectomy. Archives of Internal Medicine. 2011; 171(8).
- Lowder JL, Oliphant SS, Ghetti C, et al. Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004. Am J Obstet Gynecol. 2010; 202(6): 538.e1–538.e9.
- Jacoby VL, Vittinghoff E, Nakagawa S, et al. Factors associated with undergoing bilateral salpingo-oophorectomy at the time of hysterectomy for benign conditions. Obstet Gynecol. 2009; 113(6): 1259–1267.
- Judd HL. Hormonal dynamics associated with the menopause. Clin Obstet Gynecol. 1976; 19(4): 775–788.
- American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 119: Female sexual dysfunction. Obstet Gynecol. 2011; 117(4): 996–1007.
- Parker WH, Shoupe D, Broder MS, et al. Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol. 2007; 19(4): 350–354.
- McAlpine JN, Hanley GE, Woo MMM, et al. Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014; 210(5): 471.e1–471.11.
- Erekson EA, Martin DK, Ratner ES. Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause. 2013; 20(1): 110–114.
- Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009; 113(5): 1027–1037.
- Plusquin C, Fastrez M, Vandromme J, et al. Determinants of the decision to perform prophylactic oophorectomy in association with a hysterectomy for a benign condition. Maturitas. 2012; 73(2): 164–166.
- Vitonis AF, Titus-Ernstoff L, Cramer DW. Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol. 2011; 117(5): 1042–1050.
- Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997; 336(16): 1125–1130.
- Finch A, Beiner M, Lubinski J, et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006; 296(2): 185–192.
- Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol. 2012; 10(5): 296–306.
- Rebbeck TR, Friebel T, Wagner T, et al. PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005; 23(31): 7804–7810.
- Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23(30): 7491–7496.
- Chan JK, Urban R, Capra AM, et al. Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy. Obstet Gynecol. 2014; 123(1): 65–72.
- Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993; 270(23): 2813–2818.
- Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet. 2014; 289(2): 241–246.
- Daly MB, Dresher CW, Yates MS, et al. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila). 2015; 8(5): 342–348.
- Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol. 2008; 111(6): 1285–1292.
- Parker WH, Broder MS, Liu Z, et al. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 2005; 106(2): 219–226.
- Løkkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas. 2006; 53(2): 226–233.
- Atsma F, Bartelink MLEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13(2): 265–279.
- Michelsen TM, Pripp AH, Tonstad S, et al. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer. 2009; 45(1): 82–89.
- Allison MA, Manson JE, Langer RD, et al. Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause. 2008; 15(4 Pt 1): 639–647.
- Vearncombe KJ, Pachana NA. Is cognitive functioning detrimentally affected after early, induced menopause? Menopause. 2009; 16(1): 188–198.
- Rocca WA, Bower JH, Ahlskog JE, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007; 69(11): 1074–1083.
- Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996; 97(1): 14–21.
- Melton LJ, Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003; 18(5): 900–905.
- Antoniucci DM, Sellmeyer DE, Cauley JA, et al. Study of Osteoporotic Fractures Research Group. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women. J Bone Miner Res. 2005; 20(5): 741–747.
- Davis S, Papalia MA, Norman RJ, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med. 2008; 148(8): 569–577.
- Celik H, Gurates B, Yavuz A, et al. The effect of hysterectomy and bilaterally salpingo-oophorectomy on sexual function in post-menopausal women. Maturitas. 2008; 61(4): 358–363.
- Berek JS, Chalas E, Edelson M, et al. Society of Gynecologic Oncologists Clinical Practice Committee. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010; 116(3): 733–743.
